4931-00-4

Basic information

• Product Name: 2-hydrazino-4-methylpyridine
• Synonyms: 2-hydrazino-4-methylpyridine;pyridine, 2-hydrazino-4-methyl-;4-Methyl-2-pyridylhydrazine;2-Hydrazinyl-4-Methylpyridine;2-Hydrazino-4-picoline, (4-Methylpyridin-2-yl)hydrazine;(4-Methyl-pyridin-2-yl)-hydrazine;2-hydrazino-4-methylpyridine hydrochloride
• CAS NO: 4931-00-4
• Molecular Formula: C₆H₉N₃
• Molecular Weight: 123.15576
• Mol File: 4931-00-4.mol

Chemical Properties

• Melting Point: 74 °C
• Boiling Point: 88-89 °C(Press: 0.02 Torr)
• Appearance: /
• Density: 1.16±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 9.85±0.70(Predicted)
• CAS DataBase Reference: 2-hydrazino-4-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-hydrazino-4-methylpyridine(4931-00-4)
• EPA Substance Registry System: 2-hydrazino-4-methylpyridine(4931-00-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 4931-00-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-hydrazino-4-methylpyridine is used as a building block for the synthesis of various biologically active compounds, including potential anticancer and antiviral agents. Its unique structure allows for the development of new therapeutic agents that can target specific biological pathways, offering novel treatment options for a range of diseases.
Used in Agrochemical Industry:
In the agrochemical sector, 2-hydrazino-4-methylpyridine is utilized as a precursor in the creation of fungicidal agents. Its antifungal properties make it a key component in the formulation of new pesticides designed to combat fungal infections in crops, thereby enhancing agricultural productivity and crop protection.
Used in Industrial Applications:
2-hydrazino-4-methylpyridine has also been studied for its potential use as a corrosion inhibitor. Its ability to protect materials from corrosion makes it a candidate for use in various industrial settings, where the preservation of infrastructure and equipment is crucial for maintaining operational efficiency and safety.
Due to its versatile properties and wide range of potential applications, 2-hydrazino-4-methylpyridine is a compound of significant interest for ongoing research and development efforts in the fields of medicine, agriculture, and materials science. Its multifaceted utility underscores its importance in the advancement of new technologies and treatments.

Upstream product

• 3678-62-4 2-chloro-4-picoline 
• 461-87-0 2-fluoro-4-methylpyridine 
• 108-89-4 picoline 

Downstream Products

• 5528-57-4 7‐methyl‐2H,3H‐[1,2,4]triazolo[4,3‐a]pyridin‐3‐one 
• 4926-16-3 7-methyl-3-phenyl-[1,2,4]triazolo[4,3-a]pyridine 
• 4919-10-2 7-Methyl-s-triazolo<4,3-a>pyridin 

Relevant articles and documents

Metal free [4+1] and [5+1] annulation reactions to prepare heterocycles using DMF and its derivatives as one-carbon source

1,2,4-Triazolo[3,4-a]pyridines and related heterocycles and substituted triazines were commonly discovered scaffolds in a variety of pharmaceutical and agrochemical agents. Herein, we report a highly efficient and practical method using DMF and its derivative for the [4+1] and [5+1] annulation reactions to prepare these heterocycles. This metal free reaction takes advantages of shelf stable DMF as solvent and carbon donor, imidazole chloride as a catalyst, the mild reaction condition tolerates a broad substrate range and substitutes. The prepared 3-unsubstituted 1,2,4-triazolo[3,4-a]pyridine and derivatives allow further introduction of a variety of functional group1 at 3-position.

PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT 1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, and G, are defined herein.

Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia

Small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF-PH mimics hypoxia and leads to increased erythropoietin (EPO) expression and subsequently increased erythropoiesis. Herein we describe the discovery, synthesis, structure–activity relationship (SAR), and proposed binding mode of novel 2,4-diheteroaryl-1,2-dihydro-3H-pyrazol-3-ones as orally bioavailable HIF-PH inhibitors for the treatment of anemia. High-throughput screening of our corporate compound library identified BAY-908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85-3934), a novel small-molecule oral HIF-PH inhibitor. Molidustat is currently being investigated in clinical phase III trials as molidustat sodium for the treatment of anemia in patients with CKD.

Catalytic Coupling between Unactivated Aliphatic C-H Bonds and Alkynes via a Metal-Hydride Pathway

We report a Rh(I)-catalyzed site-selective coupling between ketone β-C(sp3)-H bonds and aliphatic alkynes using an in situ-installed directing group. Upon hydrogenation or hydration, various β-alkylation or β-aldol products of the ketones are obtained with broad functional group tolerance. Mechanistic investigations support the involvement of a Rh-H intermediate through oxidative addition of Rh(I) into the β-C-H bonds. Thus, to the best of our knowledge, this transformation represents the first example of catalytic couplings between unsaturated hydrocarbons and unactivated aliphatic C-H bonds via a metal-hydride pathway.

Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists

Previously disclosed C6 amido and benzimidazole dihydropyrazolopyrimidines were potent and selective blockers of IKur current. Syntheses and SAR for C6 triazolo and imidazo dihydropyrazolopyrimidines series are described. Trifluoromethylcyclohexyl N(1) triazole, compound 51, was identified as a potent and selective Kv1.5 inhibitor with an acceptable PK and liability profile.

TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS

Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.

SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF

The present application relates to novel substituted dipyridyldihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES

The invention relates to dihydropyrazolon-derivatives of formula (I), to methods for their production, to their use for treating and/or for preventing diseases and their use for producing medicaments for treating and/or for preventing diseases, in particular cardiovascular and haematological diseases, kidney diseases and for promoting the healing of wounds.

4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES

The object of the invention is to provide new compounds which can be used for the treatment of diseases, in particular cardiovascular and haematological diseases. The present invention describes compounds which act as specific HIF-prolyl-4-hydroxylase inhibitors and which, because of this specific in vivo action mechanism, induce HIF target genes, such as erythropoietin, and the thus produced biological processes, such as erythropoiesis, after parenteral or oral administration. The present invention relates to compounds having the general formula (I), in which A stands for CH or N, R1 stands for a substituent selected from the group formed by (C1-C6)-alkyl, trifluoromethyl, halogen, cyano, nitro, hydroxy, (C1-C6)-alkoxy, amino, (C1-C6)-alkoxycarbonyl, hydroxycarbonyl and C(=O)-NH-R4; R2 stands for a substituent selected from the group formed by halogen, cyano, nitro, (C1-C6)-alkyl, trifluoromethyl, hydroxy, (C1-C6)-alkoxy, trifluoromethoxy, amino, hydroxycarbonyl and C(=O)-NH-R8; m equals 0, 1 or 2; n equals 0, 1, 2 or 3, it being possible for these meanings to be the same or different when R1 or R2 occurs multiple times; and R3 stands for hydrogen, (C1-C6)-alkyl or (C3-C7)-cycloalkyl. The invention also relates to the salts, solvates, and salt solvates of these compounds.